CCM
CYCN icon

Camber Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Camber Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-111,353
Closed -$27M – 32
2019
Q3 		$27M Buy
111,353
+33,257
+43% +$7.18M 1.42% 27
2019
Q2 		$17.9M Buy
+78,096
New +$22.1M 0.83% 27

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $146M AUM 71.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Camber Capital Management's CYCN Position: Q4 2019 in Review

Camber Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 111,353 shares — an estimated $27M sold.

Camber Capital Management first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $27M in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • Camber Capital Management reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Camber Capital Management sold 111,353 Cyclerion Therapeutics shares in Q4 2019, an estimated $27M.
  • Camber Capital Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
  • Camber Capital Management's Cyclerion Therapeutics position peaked at $27M in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on Camber Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.